Dana M. Lewis | #OpenAPS 🤖 Profile picture
Jun 8, 2019 19 tweets 7 min read Read on X
Here is a Twitter thread from poster 117-LB at #ADA2019, DIWHY: Factors Influencing Motivation, Barriers and Duration of DIY Artificial Pancreas System Use Among Real-World Users. Image
Background

Until recently, digital innovations in healthcare have typically followed a ‘top-down’ pathway, with manufacturers leading the design and production of technology-enabled solutions and patients involved only as users of the end-product. #ADA2019
This is being disrupted by increasing influence and popularity of more ‘bottom-up’ and patient-led open source initiatives. A primary example is growing movement of people with diabetes (PwD) who create their own “Do-it-Yourself” Artificial Pancreas Systems (DIY APS). #ADA2019
Objective

Little is known about why PwD leave traditional care pathways and turn to DIY technology. This study aims to examine the motivations of current DIYAPS users and their caregivers. #ADA2019
Research Design and Methods

An online survey with 34 items was distributed to DIYAPS users recruited through the Facebook groups “Looped” (and regional sub-groups) and Twitter pages of the “DOC” (Diabetes Online Community). #ADA2019
Self-reported data was collected, managed and analyzed using the secure REDCap electronic data capture tools hosted at Charité - Universitaetsmedizin Berlin. #ADA2019
Results

1058 participants from 34 countries (81.3 % Europe, 14.7 % North America, 6.0 % Australia/WP, 3.1 % Asia, 0.1 % Africa), responded to the survey. #ADA2019
The majority were adults (80.2 %) with type 1 diabetes (98.9 %) using a DIY APS themselves (43.0 % female, 56.8 % male, 0.3 % other) with a median age of 41 y and an average diabetes duration of 25.2y ±13.3. #ADA2019
19.8 % of the participants were parents and/or caregivers of children with type 1 diabetes (99.4 %) using a DIY APS (47.4 % female, 52.6 % male) with a median age of 10 y and an average diabetes duration of 5.1y ± 3.8. #ADA2019
People used various DIYAPS (58.2% AndroidAPS, 28.5% Loop, 18.8% OpenAPS, 5.7% other) on avg for duration of 10.1months ±17.6 & reported an overall HbA1c-improvement of -0.83% (7.07%±1.07 to 6.24%±0.68) & overall TIR improvement of +19.86% (63.21%±16.27 to 83.07%±10.11). #ADA2019
Participants indicated that DIYAPS use required them to pay out-of-pocket costs in addition to their standard healthcare expenses with an average amount of 712 USD spent per year. #ADA2019
Primary motivations for building a DIYAPS were to improve the overall glycaemic control, reduce acute and long-term complication risk, increase life expectancy and to put diabetes on ‘auto-pilot’ and interact less frequently with the system. #ADA2019 Image
Lack of commercially available closed loop systems & improvement of sleep quality was motivation for some. For caregivers, improvement of own sleep quality was leading motivation. For adults, curiosity (medical or technical interest) had higher impact on motivation. #ADA2019
Some people feel that commercial systems do not suit their individual needs and prefer to use a customizable system, which is only available to them as a DIY solution. #ADA2019
Other reasons, like costs of commercially available systems and unachieved therapy goals played a subordinate role. Lack of medical or psychosocial support was less likely to be motivating factors for both groups. #ADA2019
Conclusions

Our findings suggest that people using Do-it-Yourself Artificial Pancreas systems and their caregivers are highly motivated to improve their/their children’s diabetes management through the use of this novel technology. #ADA2019
They are also able to access and afford the tools needed to use these systems. Currently approved and available commercial therapy options may not be sufficiently flexible or customizable enough to fulfill their individual needs. #ADA2019
As part of “OPEN”, results of this DIWHY survey may contribute to a better understanding of unmet needs of PwD & current challenges to uptake, which will, in turn, facilitate dialogue and collaboration to strengthen involvement of open source approaches in healthcare. #ADA2019
(You can find a longer form copy of this poster content, and all other posters co-authored by @danamlewis at bit.ly/DanaMLewisADA2…)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dana M. Lewis | #OpenAPS 🤖

Dana M. Lewis | #OpenAPS 🤖 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @danamlewis

Jun 22
1/ What if there was a tool to help identify who might have exocrine pancreatic insufficiency (EPI/PEI)?

EPI is a significant issue for many people with diabetes (likely more common than gastroparesis or celiac).

Here's how such a tool can help PWD👇🏼🧵

#ADASciSessions #ADA2024
2/ The Exocrine Pancreatic Insufficiency Symptom Score (EPI/PEI-SS) has 15 symptoms, rated by how frequent they are and how bothersome they are (aka severity).

n=324 ppl participated in a real-world survey.

n=118 were people with diabetes (PWD)!

#ADASciSessions #ADA2024
3/ Methods:

EPI/PEI-SS scores were analyzed and compared between PWD (n=118), with EPI (T1D: n=14; T2D: n=20) or without EPI (T1D: n=78; T2D: n=6), and people without diabetes (n=206) with and without EPI.

#ADASciSessions #ADA2024
Read 10 tweets
Jun 6, 2022
📣 Presentation of the primary outcome results from the CREATE Trial, which assessed open source automated insulin delivery (AID) compared to sensor-augmented pump therapy (SAPT) in adults & kids with T1D, at #ADA2022!

@DrMartindeBock1 presenting on behalf of CREATE team.

1/
Shout out to the amazing CREATE study team.

(PS - there’s another publication from our team about HCPs learning experience on open source AID for this study, too! doi.org/10.1111/dme.14…)

2/ #ADA2022
The CREATE trial aimed to study the efficacy and safety of an open source automated insulin delivery system, with a large scale, long term randomized controlled trial.

3/ #ADA2022
Read 15 tweets
Jun 5, 2022
I just realized it's been 3 (!) years since I published my book on automated insulin delivery, with the goal of helping increased conversation and understanding of AID technology for people with diabetes, their loved ones, and healthcare providers!

I'm still very proud that it is available to read for free online, free to download a PDF (both of which have been done thousands of times each: ArtificialPancreasBook.com), or as an e-book, paperback, and now hardback copy. Proceeds from the purchased copies go to Life For A Child.
And, more recently, it has also been translated into French by the wonderful Dr. Mihaela Muresan and Olivier Legendre!

The French translation is available in Kindle, paperback, hardback, or free PDF download formats as well.

Read 6 tweets
Sep 24, 2020
1/THREAD - my presentation is kicking off at #EASD2020 about open source automated insulin delivery.

(You can see a full version of my presentation here: bit.ly/DanaMLewisEASD…, or read the summary below!)
Note we should differentiate between open source (where the source of something is open), and DIY (do-it-yourself) implementations of open source code. Open source means it can be reviewed and used by individuals (thus, DIY or #DIYAPS) or by companies.

/2 #EASD2020
Open source automated insulin delivery (AID) has evolved since the first open source system, #OpenAPS, was made available in Feb 2015!

There are now three open source AID systems (OpenAPS, Loop, AndroidAPS) commonly used by the #DIYAPS community.

/3 #EASD2020
Read 25 tweets
Jun 13, 2020
THREAD:

Poster 988-P at #ADA2020 by Jennifer Zabinsky, Haley Howell, Alireza Ghezavati, @DanaMLewis Andrew Nguyen, and Jenise Wong: “Do-It-Yourself Artificial Pancreas Systems Reduce Hyperglycemia Without Increasing Hypoglycemia”

(PDF available at bit.ly/DanaMLewisADA2…)
This was a retrospective double cohort study that evaluated data from the @OpenAPS Data Commons (data ranged from 2017-2019) and compared it to conventional sensor-augmented pump (SAP) therapy from the @Tidepool_org Big Data Donation Project. #ADA2020
One month of CGM data (with more than 70% of the month spent using CGM), as long as they were >1 year of living with T1D, was used from the @OpenAPS Data Commons. People could be using any type of DIYAPS (OpenAPS, Loop, or AndroidAPS) and there were no age restrictions. #ADA2020
Read 12 tweets
Jun 13, 2020
THREAD:

Poster 99-LB at #ADA2020 by @danamlewis, @azure_dominique, and Lance Kriegsfeld, “Multi-Timescale Interactions of Glucose and Insulin in Type 1 Diabetes Reveal Benefits of Hybrid Closed Loop Systems“

(full content also available at bit.ly/DanaMLewisADA2…) Image
Background - Blood glucose and insulin exhibit coupled biological rhythms at multiple timescales, including hours (ultradian, UR) and the day (circadian, CR) in individuals without diabetes. But, biological rhythms in longitudinal data have not been mapped in T1D. #ADA2020
It is not known exactly how glucose and insulin rhythms compare between T1D and non-T1D, and whether rhythms are affected by type of therapy (Sensor Augmented Pump (SAP) or Hybrid Closed Loop (HCL)). #ADA2020
Read 26 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(